当前位置: 首页 >> 检索结果
1163. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
作者: Long V Pham.;Martin Schou Pedersen.;Ulrik Fahnøe.;Carlota Fernandez-Antunez.;Daryl Humes.;Kristian Schønning.;Santseharay Ramirez.;Jens Bukh.
来源: Gut. 2022年71卷3期627-642页
HCV-genotype 4 infections are a major cause of liver diseases in the Middle East/Africa with certain subtypes associated with increased risk of direct-acting antiviral (DAA) treatment failures. We aimed at developing infectious genotype 4 cell culture systems to understand the evolutionary genetic landscapes of antiviral resistance, which can help preserve the future efficacy of DAA-based therapy.
1164. Six-month follow-up of gut microbiota richness in patients with COVID-19.
作者: Yanfei Chen.;Silan Gu.;Yunbo Chen.;Haifeng Lu.;Ding Shi.;Jing Guo.;Wen-Rui Wu.;Ya Yang.;Yongtao Li.;Kai-Jin Xu.;Cheng Ding.;Rui Luo.;Chenjie Huang.;Ling Yu.;Min Xu.;Ping Yi.;Jun Liu.;Jing-Jing Tao.;Hua Zhang.;Longxian Lv.;Baohong Wang.;Jifang Sheng.;Lanjuan Li.
来源: Gut. 2022年71卷1期222-225页 1166. Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
作者: Zhibo Xie.;Ya Gao.;Chiakang Ho.;Lequn Li.;Chen Jin.;Xiaoyi Wang.;Caifeng Zou.;Yishen Mao.;Xiaobo Wang.;Qingfeng Li.;Deliang Fu.;Yi-Fan Zhang.
来源: Gut. 2022年71卷3期568-579页
Pancreatic ductal adenocarcinoma (PDAC) shows a remarkable predilection for liver metastasis. Pro-oncogenic secretome delivery and trafficking via exosomes are crucial for pre-metastatic microenvironment formation and metastasis. This study aimed to explore the underlying mechanisms of how PDAC-derived exosomes (Pex) modulate the liver microenvironment and promote metastasis.
1168. Long-term yield of pancreatic cancer surveillance in high-risk individuals.
作者: Kasper A Overbeek.;Iris J M Levink.;Brechtje D M Koopmann.;Femme Harinck.;Ingrid C A W Konings.;Margreet G E M Ausems.;Anja Wagner.;Paul Fockens.;Casper H van Eijck.;Bas Groot Koerkamp.;Olivier R C Busch.;Marc G Besselink.;Barbara A J Bastiaansen.;Lydi M J W van Driel.;Nicole S Erler.;Frank P Vleggaar.;Jan-Werner Poley.;Djuna L Cahen.;Jeanin E van Hooft.;Marco J Bruno.; .
来源: Gut. 2022年71卷6期1152-1160页
We aimed to determine the long-term yield of pancreatic cancer surveillance in hereditary predisposed high-risk individuals.
1169. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
作者: Laura A Bolte.;Arnau Vich Vila.;Floris Imhann.;Valerie Collij.;Ranko Gacesa.;Vera Peters.;Cisca Wijmenga.;Alexander Kurilshikov.;Marjo J E Campmans-Kuijpers.;Jingyuan Fu.;Gerard Dijkstra.;Alexandra Zhernakova.;Rinse K Weersma.
来源: Gut. 2021年70卷7期1287-1298页
The microbiome directly affects the balance of pro-inflammatory and anti-inflammatory responses in the gut. As microbes thrive on dietary substrates, the question arises whether we can nourish an anti-inflammatory gut ecosystem. We aim to unravel interactions between diet, gut microbiota and their functional ability to induce intestinal inflammation.
1173. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.
作者: Jin Zhou.;Zhong Wu.;Zhouwei Zhang.;Louisa Goss.;James McFarland.;Ankur Nagaraja.;Yingtian Xie.;Shengqing Gu.;Ke Peng.;Yong Zeng.;Xiaoyang Zhang.;Henry Long.;Hiroshi Nakagawa.;Anil Rustgi.;J Alan Diehl.;Matthew Meyerson.;Kwok-Kin Wong.;Adam Bass.
来源: Gut. 2022年71卷4期665-675页
Oesophageal squamous cell carcinoma (OSCC), like other squamous carcinomas, harbour highly recurrent cell cycle pathway alterations, especially hyperactivation of the CCND1/CDK4/6 axis, raising the potential for use of existing CDK4/6 inhibitors in these cancers. Although CDK4/6 inhibition has shown striking success when combined with endocrine therapy in oestrogen receptor positive breast cancer, CDK4/6 inhibitor palbociclib monotherapy has not revealed evidence of efficacy to date in OSCC clinical studies. Herein, we sought to elucidate the identification of key dependencies in OSCC as a foundation for the selection of targets whose blockade could be combined with CDK4/6 inhibition.
1174. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19.
作者: Zhigang Ren.;Haiyu Wang.;Guangying Cui.;Haifeng Lu.;Ling Wang.;Hong Luo.;Xinhua Chen.;Hongyan Ren.;Ranran Sun.;Wenli Liu.;Xiaorui Liu.;Chao Liu.;Ang Li.;Xuemei Wang.;Benchen Rao.;Chengyu Yuan.;Hua Zhang.;Jiarui Sun.;Xiaolong Chen.;Bingjie Li.;Chuansong Hu.;Zhongwen Wu.;Zujiang Yu.;Quancheng Kan.;Lanjuan Li.
来源: Gut. 2021年70卷7期1253-1265页
To characterise the oral microbiome, gut microbiome and serum lipid profiles in patients with active COVID-19 and recovered patients; evaluate the potential of the microbiome as a non-invasive biomarker for COVID-19; and explore correlations between the microbiome and lipid profile.
1175. Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.
作者: Manuel Zorzi.;Jessica Battagello.;Kevin Selby.;Giulia Capodaglio.;Susanna Baracco.;Silvia Rizzato.;Enrico Chinellato.;Stefano Guzzinati.;Massimo Rugge.
来源: Gut. 2022年71卷3期561-567页
The risk of colorectal cancer (CRC) among subjects with a positive faecal immunochemical test (FIT) who do not undergo a colonoscopy is unknown. We estimated whether non-compliance with colonoscopy after a positive FIT is associated with increased CRC incidence and mortality.
1177. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
作者: Calvin Q Pan.;Erhei Dai.;Zhongping Duan.;Guorong Han.;Wenjing Zhao.;Yuming Wang.;Huaihong Zhang.;Baoshen Zhu.;Hongxiu Jiang.;Shuqin Zhang.;Xiaohu Zhang.;Huaibin Zou.;Xiuli Chen.;Yu Chen.
来源: Gut. 2022年71卷4期798-806页
The physical and neuromental development of infants remains uncertain after fetal exposure to tenofovir disoproxil fumarate (TDF) for the prevention of mother-to-child transmission of HBV. We aimed to investigate the safety of TDF therapy during the third trimester of pregnancy.
1178. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
作者: Xiaochuan Dong.;Shumei Song.;Yuan Li.;Yibo Fan.;Lulu Wang.;Ruiping Wang.;Longfei Huo.;Ailing Scott.;Yan Xu.;Melissa Pool Pizzi.;Lang Ma.;Ying Wang.;Jiangkang Jin.;Wei Zhao.;Xiaodan Yao.;Randy L Johnson.;Linghua Wang.;Zhenning Wang.;Guang Peng.;Jaffer A Ajani.
来源: Gut. 2022年71卷3期467-478页
Gastric adenocarcinoma (GAC) is a lethal disease with limited therapeutic options. Genetic alterations in chromatin remodelling gene AT-rich interactive domain 1A (ARID1A) and mTOR pathway activation occur frequently in GAC. Targeting the mechanistic target of rapamycin (mTOR) pathway in unselected patients has failed to show survival benefit. A deeper understanding of GAC might identify a subset that can benefit from mTOR inhibition.
1180. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial.
作者: Siew C Ng.;Zhilu Xu.;Joyce Wing Yan Mak.;Keli Yang.;Qin Liu.;Tao Zuo.;Whitney Tang.;Louis Lau.;Rashid N Lui.;Sunny H Wong.;Yee Kit Tse.;Amy Y L Li.;Kitty Cheung.;Jessica Y L Ching.;Vincent W S Wong.;Alice P S Kong.;Ronald C W Ma.;Elaine Y K Chow.;Simon K H Wong.;Ivan Chak Hang Ho.;Paul K S Chan.;Francis K L Chan.
来源: Gut. 2022年71卷4期716-723页
The impact of faecal microbiota transplantation (FMT) on microbiota engraftment in patients with metabolic syndrome is uncertain. We aimed to study whether combining FMT with lifestyle modification could enhance the engraftment of favourable microbiota in obese patients with type 2 diabetes mellitus (T2DM).
|